Evidence map›Paper›PMID 42663691›Full record

ReviewAntonie van Leeuwenhoek2026

Weissella as an emerging probiotic candidate for IBD: current evidence, challenges, and future perspectives".

Hima Sebastian, Blaze Babu, K M Gayathri, Pranavya Susheel, Neha Sreenivas, Sneha Yogindran, Sarita G Bhat

Abstract readReview
PubMed Publisher
In one paragraph

Review in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hima SebastianDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India.
Blaze BabuDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India.
K M GayathriDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India.
Pranavya SusheelDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India.
Neha SreenivasDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India.
Sneha YogindranDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India.
Sarita G BhatDepartment of Biotechnology, Cochin University of Science and Technology, Cochin, Kerala, India. sgbhat@cusat.ac.in.

Funding

Indian Council of Medical Research IIRPSG-2024-01-01903
6 · The paper itself

Abstract

Inflammatory Bowel Disease (IBD) is a chronic, relapsing inflammatory affliction that causes gut dysbiosis, impaired mucosal integrity and disrupted immune regulation/responses. Conventional therapies, which aim to suppress inflammation or immune flare-ups, are associated with adverse effects and have limited long-term management efficacy. Therefore, the focus has shifted to the use of microbe-mediated therapeutics, such as multi-strain probiotic blends, for alleviating inflammation and lengthening the relapse period. Within this context, Weissella is an emerging and underexplored genus of Lactic acid bacteria with unique metabolic and immunomodulatory properties.This review consolidates current insights on Weissella SP., particularly W. confusa and W. cibaria, focusing on their probiotic attributes, safety profiles, molecular mechanisms, and performance in pre-clinical models of colitis. Evidence shows that this genus can help decrease pro-inflammatory cytokines, enhancing mucosal integrity via strengthening tight-junction proteins, and supporting goblet cell recovery. Despite encouraging pre-clinical findings, comprehensive safety studies and human clinical data are limited. Hence, this review outlines critical research gaps and future directions, positioning Weissella as an underexplored yet promising component of next-generation probiotic blends for IBD therapeutics.

Indexed as

Inflammatory Bowel DiseasesProbioticsWeissellaAnimalsGastrointestinal MicrobiomeHumansColitisGut microbiotaInflammatory Bowel Disease (IBD)Lactic acid bacteriaProbiotic blendsProbioticsWeissella

Identifiers

PMID42663691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.